533 related articles for article (PubMed ID: 27148964)
1. High Proportion of HIV-HCV Coinfected Patients with Advanced Liver Fibrosis Requiring Hepatitis C Treatment in Haiphong, Northern Vietnam (ANRS 12262).
Nguyen Truong T; Laureillard D; Lacombe K; Duong Thi H; Pham Thi Hanh P; Truong Thi Xuan L; Chu Thi N; Luong Que A; Vu Hai V; Nagot N; Tuaillon E; Dominguez S; Lemoine M
PLoS One; 2016; 11(5):e0153744. PubMed ID: 27148964
[TBL] [Abstract][Full Text] [Related]
2. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
[TBL] [Abstract][Full Text] [Related]
3. Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.
Loko MA; Bani-Sadr F; Winnock M; Lacombe K; Carrieri P; Neau D; Morlat P; Serfaty L; Dabis F; Salmon D;
J Viral Hepat; 2011 Jul; 18(7):e307-14. PubMed ID: 21692942
[TBL] [Abstract][Full Text] [Related]
4. Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.
Maida I; Martin-Carbonero L; Sotgiu G; Vispo E; Barreiro P; Gonzalez-Lahoz J; Soriano V
J Viral Hepat; 2010 Dec; 17(12):866-71. PubMed ID: 20088891
[TBL] [Abstract][Full Text] [Related]
5. Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy.
Fernández-Montero JV; Barreiro P; Vispo E; Labarga P; Sánchez-Parra C; de Mendoza C; Treviño A; Soriano V
Antivir Ther; 2014; 19(3):287-92. PubMed ID: 24192598
[TBL] [Abstract][Full Text] [Related]
6. Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
Durier N; Yunihastuti E; Ruxrungtham K; Kinh NV; Kamarulzaman A; Boettiger D; Widhani A; Avihingsanon A; Huy BV; Syed Omar SF; Sanityoso A; Chittmittrapap S; Dung NT; Pillai V; Suwan-Ampai T; Law M; Sohn AH; Matthews G
J Viral Hepat; 2017 Mar; 24(3):187-196. PubMed ID: 27917597
[TBL] [Abstract][Full Text] [Related]
7. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study.
Bailey H; Nizova N; Martsynovska V; Volokha A; Malyuta R; Cortina-Borja M; Thorne C;
BMC Infect Dis; 2016 Dec; 16(1):755. PubMed ID: 27955711
[TBL] [Abstract][Full Text] [Related]
8. Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapies.
Labarga P; Fernández-Montero JV; López M; Barreiro P; de Mendoza C; Sierra-Enguita R; Treviño A; Soriano V
Antivir Ther; 2014; 19(8):799-803. PubMed ID: 24964405
[TBL] [Abstract][Full Text] [Related]
9. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
[TBL] [Abstract][Full Text] [Related]
10. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
Castera L; Winnock M; Pambrun E; Paradis V; Perez P; Loko MA; Asselineau J; Dabis F; Degos F; Salmon D
HIV Med; 2014 Jan; 15(1):30-9. PubMed ID: 24007567
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
Benhamou Y; Di Martino V; Bochet M; Colombet G; Thibault V; Liou A; Katlama C; Poynard T;
Hepatology; 2001 Aug; 34(2):283-7. PubMed ID: 11481613
[TBL] [Abstract][Full Text] [Related]
12. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Casado JL; Mena A; Bañón S; Castro A; Quereda C; Moreno A; Pedreira J; Moreno S
HIV Med; 2016 Jan; 17(1):62-7. PubMed ID: 26122981
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and predictors of liver disease in HIV-infected children and adolescents.
Pokorska-Śpiewak M; Stańska-Perka A; Popielska J; Ołdakowska A; Coupland U; Zawadka K; Szczepańska-Putz M; Marczyńska M
Sci Rep; 2017 Sep; 7(1):12309. PubMed ID: 28951598
[TBL] [Abstract][Full Text] [Related]
14. Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus.
Collazos J; Cartón JA; Asensi V
Curr HIV Res; 2011 Jul; 9(5):339-45. PubMed ID: 21827383
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Fibrosis Progression in HIV-Hepatitis C Virus Co-Infection--The Effect of Sex on Risk of Significant Fibrosis Measured by Aspartate-to-Platelet Ratio Index.
Rollet-Kurhajec KC; Moodie EE; Walmsley S; Cooper C; Pick N; Klein MB;
PLoS One; 2015; 10(6):e0129868. PubMed ID: 26090666
[TBL] [Abstract][Full Text] [Related]
16. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
17. Combination Antiretroviral Therapy Is Associated With Reduction in Liver Fibrosis Scores in HIV-1-Infected Subjects.
Li Y; Xie J; Han Y; Wang H; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Zhu T; Thio CL; Li T
Medicine (Baltimore); 2016 Feb; 95(5):e2660. PubMed ID: 26844493
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of hepatic fibrosis in HIV/HCV co-infected individuals in Yaoundé, Cameroon: usefulness of APRI score in resource-constrained settings.
Dobseu R; Nanfack A; Kowo M; Ambada G; Kamgaing R; Chenwi C; Fainguem N; Ka'e A; Ngangoum E; Sosso S; Tchiegang C; Ndjolo A
BMC Infect Dis; 2020 Oct; 20(1):758. PubMed ID: 33059627
[TBL] [Abstract][Full Text] [Related]
19. Liver stiffness and aspartate aminotransferase levels predict the risk for liver fibrosis progression in hepatitis C virus/HIV-coinfected patients.
Gonzalez FA; Van den Eynde E; Perez-Hoyos S; Navarro J; Curran A; Burgos J; Falcó V; Ocaña I; Ribera E; Crespo M
HIV Med; 2015 Apr; 16(4):211-8. PubMed ID: 25234826
[TBL] [Abstract][Full Text] [Related]
20. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study.
Jiménez-Sousa MA; Berenguer J; Fernández-Rodríguez A; Medrano LM; Aldámiz-Echevarria T; Pérez-Latorre L; Díez C; Martín-Vicente M; Gutiérrez-Rivas M; Martínez I; Resino S
Infect Genet Evol; 2019 Jan; 67():112-120. PubMed ID: 30336268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
